Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (4067)	4/16/1998 11:29:00 AM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Margie (edited), I doubt this has much to with options expiration...I believe what you're seeing is extreme disappointment. The investment community had much higher hopes then the story AGPH seemed to paint. I would guess there is quickly building concern that R&D costs and competition might bury the company before they get other drugs solidly established in the market. I'm disappointed...not in the numbers but the future story. It somehow seems less clear then last week. Any slip in Viracept marketshare may spell real bad news in the short term. Looks like I may need to do something with my options positions...can't risk letting it get away from me again. It's looking to me like there was logic behind the relatively heavy insider sales. Not necessarily that they were trading on inside information or anything illegal, but instead on gut feel. We're talking about a company that doesn't even know what countries their products are being sold in, sure we can blame Roche, but there's just no excuse for this IMO. I've got too much riding on this stock for a company that seems to have so much to learn from a business standpoint. I firmly believe you're seeing investors bailing, reducing positions, and an whole new wave of short selling. Now it's not just Montgomery, we've got Morgan Stanly. Although it was just a downgrade to outperform, sure sounds like the beginnings of weasling out of their bullish strong buy rating. I don't even want to know what Ms Wang is saying right now. sf

To: margie who wrote (4067)	4/16/1998 12:00:00 PM
From: Steve Fancy	Respond to of 6136

>>Paine Weber just issued a 4 page report repeating the same bullish position they have had...<< Margie, PW is maintaining their $70-$75 price target? This was their 12 month price target going way back last year I believe. I think the year is almost up. I've lost most all confidence in Ms Wang. sf

To: margie who wrote (4067)	4/16/1998 4:31:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Margie, of all the gin joints, you have to walk into this one ... : ) you said: "Paine Weber just issued a 4 page report repeating the same bullish position they have had, as well as another report showing strong monthly scrips. And Agouron's market share is up close to 5% for the month of March, and the combined Invirase/fortovase market share is down slightly. And I don't feel like wasting my time trying to post the figures here, it takes too long. And it doesn't make a difference. They are better, trust me :-)" Please do take the time to post the numbers ... they are extremely helpful, and it does make a big difference. Thanks! Peter